De medewerkers van SHM geven met regelmaat presentaties waarin bevindingen uit onderzoek en publicaties worden gepresenteerd. Een groot gedeelte van de presentaties is Engelstalig. Hieronder vindt u een overzicht van de presentaties in 2003.
Tremendous savings in hospital-based AIDS care have been reported over the first few years since HAART became widely available in 1996. However, longer term HAART may result in increasing costs, due to toxicity of antiretroviral regimens and development of viral resistance and subsequent therapy failure. We determined whether the direct costs of HIV treatment have changed over recent years. On a population level, the per capita costs of HAART in the Netherlands have continued to decrease up to July 2003, but seemed to have reached a nadir. Long-term use of HAART is associated with increased expenditure on inpatient hospital resources and initiation of HAART appears more expensive recently than previously reported.